Skip to Content

Accolate (zafirlukast) Disease Interactions

There is 1 disease interaction with Accolate (zafirlukast):

Major

Zafirlukast (Includes Accolate) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

The use of zafirlukast may be associated with elevations of one or more liver enzymes as well as life-threatening hepatic failure. Cases of liver injury without other attributable cause have been reported from postmarketing surveillance of patients treated with the recommended dosage of zafirlukast (40 mg/day). Although most cases have been reversible following drug discontinuation, fulminant hepatitis and progression to hepatic failure, liver transplantation, and death have been reported rarely. Zafirlukast is also primarily metabolized by the liver. In patients with hepatic cirrhosis, serum zafirlukast concentrations may be 50% to 60% higher than in normal patients. Because of the hepatotoxic effects, potential for accumulation, and lack of data regarding treatment in patients with hepatic impairment, therapy with zafirlukast should be administered cautiously in such patients. Periodic serum transaminase testing is recommended to enable early detection of drug-induced hepatic injury, and patients should be advised to contact their physician immediately if they experience signs or symptoms of liver dysfunction (e.g., right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, anorexia, and enlarged liver). Zafirlukast should be discontinued and liver function tests performed immediately if hepatic injury is suspected. The drug should not be resumed if hepatic injury is confirmed. Patients in whom zafirlukast was withdrawn because of hepatic injury where no other attributable cause is identified should not be re-exposed to zafirlukast.

References

  1. Kelloway JS "Zafirlukast: the first leukotriente-receptor antagonist approved for the treatment of asthma." Ann Pharmacother 31 (1997): 1012-21
  2. Spector SL "Leukotriene inhibitors and antagonists in asthma." Ann Allergy Asthma Immunol 75 (1995): 463-70,473-4
  3. Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ "Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast." Ann Intern Med 133 (2000): 964-8
View all 4 references

Accolate (zafirlukast) drug Interactions

There are 277 drug interactions with Accolate (zafirlukast)

Accolate (zafirlukast) alcohol/food Interactions

There is 1 alcohol/food interaction with Accolate (zafirlukast)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide